FDA Grants Orphan Drug Designation to Biompharma’s Bi104, a microbiome-modifying biologic, for the treatment of Angelman Syndrome
08 mai 2024 09h25 HE
|
Biom Pharmaceutical Corporation
Sarasota, Florida, May 08, 2024 (GLOBE NEWSWIRE) -- BIOM Pharmaceutical Corporation is thrilled to announce that Bi104, its innovative drug product, has been granted orphan-drug designation by the...
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
18 mars 2024 08h55 HE
|
PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules
15 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla Biotech contracted with Filament Health to manufacture a second batch of MDMA capsules; manufacturing is complete and shipped to clients.
Berkshire Sterile Manufacturing to Host Webinar on Intravitreal Drug Product Manufacturing
31 oct. 2023 14h00 HE
|
Berkshire Sterile Manufacturing
Lee, MA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM) will host a webinar focusing on the manufacturing of Intravitreal (IVT) drug products on Wednesday, November 15 at...
PharmAla Begins Trading on OTCQB
06 sept. 2023 08h55 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:PMBHF), a biotechnology company focused on the...
PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA
16 mai 2023 11h37 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing...
PROVECTUS BIOPHARMACEUTICALS EXPANDS PATENT PORTFOLIO WITH ADOPTIVE CELL TRANSFER-BASED USE OF INVESTIGATIONAL CANCER DRUG
18 sept. 2018 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed the Company’s patent application for...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATIONS AT SMR 2018 CONGRESS
11 sept. 2018 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from two ongoing clinical trials, single agent PV-10 and PV-10 in combination with checkpoint...
Regulatory history and reliable on-time delivery beat cost and capacity as the most important selection attributes for drug product CMOs
08 févr. 2017 11h30 HE
|
Industry Standard Research
CARY, NC--(Marketwired - February 08, 2017) - The 2nd edition of Industry Standard Research's (ISR's) Drug Product Contract Manufacturer Quality Benchmarking report reveals that buyers of outsourced...